RSV Vaccine

Learn about the options available to protect your baby from Respiratory Syncytial Virus (RSV).

Quick Facts

  • RSV is a common virus that infects the nose, throat, and lungs.

    RSV is most active in the fall and winter months and spreads easily through coughing, sneezing, and touching contaminated surfaces. It usually causes mild cold-like symptoms, but for babies and older adults, it can lead to serious illness.

  • Newborns are at the highest risk of severe RSV.

    Babies under 6 months are more likely to get very sick from RSV and need hospital care. RSV can cause serious breathing problems and lead to lung infections like bronchiolitis and pneumonia. It is a leading cause of hospitalization in babies under 1 year old.

  • There are new options available to help protect your baby from RSV.

    Pregnant individuals can receive the RSVpreF vaccine during pregnancy, or newborns can get an RSV antibody (Nirsevimab) after birth. The best option depends on personal preference, cost, and availability in your area.

  • The RSVpreF vaccine is recommended between 32 and 36 weeks of pregnancy.

    Getting the RSVpreF vaccine during pregnancy allows protective antibodies to pass through the placenta to your baby. These antibodies help protect your baby from RSV in their first few months, when they are most vulnerable.

  • The RSVpreF vaccine helps protect babies from severe RSV and hospital stays.

    Babies born to parents who were vaccinated during pregnancy are much less likely to get seriously ill or need hospital care. The vaccine helps protect your baby against serious RSV illness for up to 6 months after birth.

  • The RSVpreF vaccine is safe for pregnant individuals and their babies.

    This vaccine was specifically designed for use during pregnancy and carefully studied in pregnant individuals worldwide. Clinical trials and real-world data confirm that it is safe and effective in protecting pregnant individuals and their babies.

Protecting Against RSV

Respiratory Syncytial Virus (RSV) is a highly contagious virus that can cause serious illness in young babies. About 20 to 30% of babies who get RSV develop serious infections like bronchiolitis (inflammation of the small airways) or pneumonia (lung infection).¹⁻³ Fortunately, there are options available to help protect babies from severe RSV illness:

  1. The maternal RSV vaccine (RSVpreF) given during pregnancy.

  2. The infant RSV antibody (Nirsevimab) given to babies after birth.

Both options are safe and effective in lowering your baby’s risk of getting a serious RSV infection and ending up in the hospital. Choosing between the maternal vaccine or the infant antibody depends on your personal preference, the availability of each product in your province or territory, and cost.

  • Young pregnant woman receiving medical patch after vaccination in clinic

    Maternal RSV Vaccine (RSVpreF)

    The maternal RSV vaccine (Abrysvo™) is given during pregnancy to help protect newborns from serious illness caused by RSV. It’s recommended between 32 and 36 weeks of pregnancy and works by helping your body make protective antibodies that are passed to your baby before birth. This vaccine was specially developed for use in pregnancy and has been tested among pregnant people worldwide.⁴

    Learn More

  • Infant RSV Antibody (Nirsevimab)

    The infant RSV antibody (Nirsevimab) is a one-time injection given shortly after birth to help protect babies from serious illness caused by RSV.⁴ Unlike vaccines, which help the body build its own protection, this injection gives babies ready-made antibodies that start working to protect them right away. The protection lasts through the first few months of life, when babies are most at risk from RSV.⁴

    Learn More

About RSV

Respiratory syncytial virus (RSV) is a common seasonal virus that spreads easily from person to person. Each year, RSV causes millions of hospitalizations and around 120,000 deaths worldwide in children under the age of five.⁵

RSV is especially dangerous for babies in their first 6 months of life.²˒⁶ A study of children’s hospitals across Canada found:

  • Half of all RSV hospitalizations were in babies under 6 months old.²

  • Nearly 40% were in babies between 0 and 2 months old.²

  • About 60% of babies who needed intensive care were between 0 and 5 months old.²

RSV infections usually start with symptoms like a runny nose, dry cough, low-grade fever, sore throat, and sneezing. But in young babies, it can become more serious and lead to bronchiolitis (inflammation of the small airways in the lungs) or pneumonia, which can cause severe cough, wheezing, and difficulty breathing.

  • When someone with RSV coughs or sneezes, tiny droplets with the virus go into the air. If you breathe in these droplets, you can get infected.

    You can also catch RSV by touching a surface (like a toy, table, or doorknob) that has the virus on it, and then touching your eyes, nose, or mouth before washing your hands.

    RSV can also spread through close contact, like kissing a baby or child who has RSV.

  • Babies under 6 months old are at the highest risk of getting very sick with RSV and ending up in the hospital. The risk goes down as babies get older, but RSV can still cause serious illness after six months.4

    RSV can lead to serious complications, including:

    • Pneumonia (infection of the lungs)

    • Bronchitis or bronchiolitis (inflammation of the small airways in the lungs)

    • Apnea (slow or stopped breathing)

    In some cases, RSV can be life-threatening. Most deaths from RSV happen in babies under 3 months old.1, 7 Some babies are more likely to get very sick from RSV, including those born prematurely, those with lung or heart conditions, and babies with Down syndrome.1

  • During pregnancy, your body works harder to support your growing baby. You’re breathing for two and pumping blood for two, meaning your heart and lungs are doing extra work to keep you both healthy. These changes can make it harder for your body to fight off infections.

    Respiratory infections like RSV can be harder on your body during pregnancy and may lead to complications for you and your baby, even if you are otherwise healthy.

    There are only a few reports of severe RSV infections in pregnant people that required hospital or intensive care.⁸ We still have limited information about how often RSV happens during pregnancy or how serious it can be. This is partly because, until recently, doctors didn't routinely test pregnant people with respiratory infections to identify the specific germ causing the illness.

  • RSV is very common. In Canada, most RSV infections occur between the fall and the early spring. RSV is the leading cause of serious lung infections like bronchiolitis (swelling of the small airways) and pneumonia (lung infection) in babies and young children.¹

    • About 20 to 30% of babies who get RSV will develop bronchiolitis or pneumonia.¹

    • Nearly 1 in 4 children with RSV need care in an intensive care unit (ICU).²

    • About 60% of RSV-related ICU admissions are in babies under 6 months old.²

  • Since 2023, there are new options available in Canada to help protect young babies from severe illness and hospitalization caused by RSV:

    • Maternal RSVpreF vaccine (Abrysvo™): Given between 32 and 36 weeks of pregnancy, this vaccine helps your body create protective antibodies that are passed to your baby before birth. These antibodies help protect your baby during the first months of life, when the risk from RSV is highest.

    • Infant RSV antibody (Nirsevimab): A one-time injection given to babies shortly after they are born. It provides ready-made antibodies that help protect your baby against RSV during their first few months of life, when they are most vulnerable.

    The choice between the maternal vaccine and the infant RSV antibody depends on your personal preference, the availability of each product in your province or territory, and cost. Talk to your healthcare provider for more information on what's available in your province or territory.

RSV is most dangerous for babies during their first six months of life.

Maternal RSV Vaccine (RSVpreF)

The RSVpreF vaccine (Abrysvo™ by Pfizer) was approved by Health Canada in 2023 to help protect newborns from serious illness caused by RSV.⁴ It is the only RSV vaccine recommended for use during pregnancy in Canada.

This vaccine is specially designed for pregnant people and has been tested in pregnant individuals around the world.

  • It is given between 32 and 36 weeks of pregnancy.⁴

  • After vaccination, your body makes infection-fighting antibodies that pass through the placenta to your baby.

  • These antibodies help protect your baby during their first few months of life, when they are most at risk of serious RSV illness.

  • The vaccine targets the two most common types of RSV in Canada and can help protect your baby up to 6 months after birth.⁴

  • Vaccines work by training your immune system to recognize and fight off harmful viruses—without making you sick. They do this by safely introducing a small, harmless piece of the virus to your body. This teaches your immune system how to recognize the virus and respond if you’re exposed to it later.

    • The RSVpreF vaccine contains harmless proteins from the two most common types of RSV (RSV-A and RSV-B).¹⁰ These proteins can’t cause an infection, but they help your immune system recognize RSV and learn how to respond if you’re exposed to it in the future.

    • Within about two weeks of getting the RSVpreF vaccine, your body produces protective antibodies against the RSV virus. During pregnancy, these antibodies naturally pass through the placenta to your baby, helping protect them after birth.

    • These antibodies help protect your baby against serious RSV illness and hospitalization during their first few months of life, when they are most vulnerable.4

  • The RSVpreF vaccine helps your immune system prepare to fight off RSV without causing an actual infection.

    • The vaccine contains safe, harmless proteins from the two most common types of RSV: RSV-A and RSV-B.10

    • When your immune system detects these proteins, it produces protective antibodies against the virus.

    • During pregnancy, these antibodies naturally pass through the placenta to your baby. This provides early protection against RSV during their first few months of life, when they are most vulnerable to serious illness. Some antibodies may also be passed through breastmilk.10

    See video: How Vaccines Protect Moms and Babies

  • Getting the RSVpreF vaccine during pregnancy helps protect your baby from severe RSV illness in their first few months of life. While babies whose parent received the vaccine can still get RSV, they’re much less likely to become seriously ill or need hospital care.

    Clinical studies show that the maternal RSV vaccine helps protect babies by:

    • Reducing the risk of severe RSV illness by about 82% in the first 3 months after birth, and about 69% in the first 6 months after birth.10

    • Lowering the chance of RSV-related hospitalization by about 68% in the first 3 months, and about 57% in the first 6 months after birth.10

    • Helping prevent serious complications from RSV, such as low oxygen levels, needing a breathing machine, or being admitted to an intensive care unit (ICU).10

    The vaccine is given to pregnant people between 32 and 36 weeks of pregnancy. After you get the vaccine, it takes about 2 weeks for your body to make protective antibodies that can be passed to your baby. That’s why it’s important to get the vaccine at least 2 weeks before your baby is born.

Infant RSV Antibody (Nirsevimab)

The RSV infant antibody (Nirsevimab) contains pre-made antibodies in a single shot given to babies shortly after birth. This type of protection is called passive immunization, where the body is given ready-made defences (antibodies) rather than having to produce them. Nirsevimab works by attaching to the RSV virus and preventing it from entering your baby’s cells, stopping the virus from spreading and causing illness.9

Studies have shown that Nirsevimab protects babies from severe RSV illness and hospitalization for at least 5 months after they are born, which covers a typical RSV season.9 This early protection is important because babies are most vulnerable to getting very sick with RSV in their first few months of life.

As of 2025, Nirsevimab is available in some provinces and territories in Canada, but not others. Talk to your healthcare provider to find out if it’s available in your area.

  • The infant RSV antibody (Nirsevimab) contains pre-made antibodies and is given to babies as a single shot shortly after birth. Since these antibodies are already made, your baby doesn’t need to produce them on their own. This type of protection is known as passive immunization.

    Nirsevimab works by attaching to the RSV virus and blocking it from entering cells. It has been shown to protect babies from severe RSV illness and hospitalization for at least 5 months after birth, covering a typical RSV season.9

  • Nirsevimab provides pre-made antibodies, meaning your baby doesn’t need to make these antibodies themselves. This type of protection is called passive immunization, where the body is given ready-made defences (antibodies) rather than having to produce them.

    Once in the body, these antibodies attach to the RSV virus and block it from entering cells. By preventing the virus from getting inside cells, Nirsevimab stops RSV from spreading and causing illness. This helps protect your baby from serious RSV infections.

  • The infant RSV antibody helps protect babies from severe RSV illness. Babies who receive this immunization shortly after birth can still catch RSV, but the chances of them becoming seriously ill or needing to be hospitalized are much lower.

    While it doesn’t prevent all RSV infections, Nirsevimab lowers a baby’s risk of hospitalization from RSV by 80-90% in their first RSV season.4 Babies are protected as soon as they receive the shot.

    Nirsevimab has been shown to protect babies from severe RSV illness and hospitalization for at least 5 months after birth, covering the length of a typical RSV season.9

  • As of 2025, Nirsevimab is available in some provinces and territories in Canada, but not others. Each region makes independent decisions about offering it based on factors like supply, budget, and program priorities.

    Provinces such as Ontario, Quebec, Yukon, and Nunavut currently offer Nirsevimab free of charge to all eligible infants. However, other provinces like Alberta and Saskatchewan do not currently offer Nirsevimab through their public health programs. Instead, they continue to use an older monoclonal antibody (Palivizumab) that requires monthly injections throughout the RSV season. Palivizumab is only available for high-risk infants, such as those born prematurely or with certain medical conditions.

    Some provinces may expand access to Nirsevimab in future RSV seasons. Talk to your healthcare provider to find out if it’s available in your area.

Which Option is Best for Me and My Baby?

Currently, only one option (the maternal vaccine OR the infant antibody) is recommended to protect newborns, although this may change in the future. When deciding between the maternal RSV vaccine (RSVpreF) or the infant RSV antibody (Nirsevimab), factors like availability, cost, and personal preference may play a role. Each option has its benefits, and the best choice will depend on your unique situation. Talk to your healthcare provider to learn what’s available and what’s best for you and your baby.

Infant RSV antibody (Nirsevimab)

  • As of 2025, the RSV antibody (Nirsevimab) is available in some provinces and territories, but not others. Each province and territory decides whether to offer Nirsevimab based on factors like supply, budget, and health program priorities.

  • In some regions, Nirsevimab is only available for high-risk babies, such as those born prematurely (before 37 weeks), babies with lung or heart conditions, or those born in very remote areas.

  • As of fall 2024, Ontario, Quebec, and Nunavut are offering Nirsevimab for free to all babies in their first RSV season and high-risk children up to 24 months old.

  • Some provinces do not currently offer Nirsevimab but continue to use an older monoclonal antibody, known as Palivizumab. Palivizumab is only available for high-risk babies. Unlike Nirsevimab, it requires monthly injections throughout RSV season.

  • Nirsevimab may become available in more provinces in future RSV seasons. Talk to your healthcare provider for more information on what is currently available in your area.

Maternal RSV vaccine (RSVpreF)

  • As of 2025, the RSVpreF vaccine is only publicly funded in Ontario, where eligible pregnant individuals can get it for free.

  • In most other provinces and territories, the maternal RSVpreF vaccine can be purchased at select pharmacies with a prescription from a healthcare provider. Some private insurance plans may help cover the cost.

  • Talk to your healthcare provider for more information on the cost of the RSVpreF vaccine and where to get it in your area.

RSV Vaccine Safety

  • Yes, the maternal RSVpreF vaccine is safe to receive during pregnancy. The vaccine uses an inactive (dead) piece of the RSV virus to teach your immune system to recognize and fight the real virus if you come into contact with it. This means the maternal RSV vaccine can't give you an RSV infection or cause harm to your baby because it does not contain a ‘live’ virus.

    RSVpreF (AbrysvoTM, Pfizer) is the only RSV vaccine recommended for pregnant people in Canada.

  • No, the RSVpreF vaccine does not increase the risk of complications during pregnancy or birth. In fact, getting the vaccine helps protect both you and your baby by reducing the risk of severe RSV infections.

    The approval process for this vaccine was unique because pregnant individuals were included in the clinical trials, providing strong evidence that the vaccine is safe and effective during pregnancy.

    Here’s what the studies show:

    • In studies conducted in Argentina and South Africa, preterm births (babies born before 37 weeks) occurred in 5.6% of pregnant people vaccinated between 24 and 36 weeks of pregnancy, compared to 4.7% of those who did not get the vaccine.10-12

    • When the vaccine was given during the recommended period of 32 to 36 weeks of pregnancy, preterm births occurred in 4.2% of vaccinated pregnant people compared to 3.7% of those unvaccinated.10-12 These small differences were not statistically significant, meaning they could have happened by chance.

    • It's important to know that in Canada, up to 8% of babies are born prematurely, which is the typical rate for the general population. This means the rates of preterm births seen in the study are lower than what we expect in real life.4

    • In regions like Canada, the US, and Europe, studies have shown no difference in the rate of preterm births between those who received the RSVpreF vaccine and those who didn’t.4,13

    • There is also no evidence that the RSVpreF vaccine affects future fertility or increases the risk of miscarriage.4,13

  • Neither you nor your baby can catch RSV from the maternal RSVpreF vaccine because it does not contain a live virus. The maternal RSVpreF vaccine recommended during pregnancy is inactivated, meaning it uses a harmless, non-living piece of the RSV virus (proteins) that can't make you or your baby sick.

    Similarly, there is no risk of getting RSV from the infant antibody (Nirsevimab) because it only contains antibodies that neutralize the virus, not the virus itself.

  • After getting the maternal RSVpreF vaccine, some people may feel tired or have soreness in the arm where the injection was given. These side effects usually last from a few hours to a couple of days and are normal signs that your body is building protection against RSV. Serious side effects are rare and typically limited to the injection site, such as soreness or tenderness in the muscle where the shot was given.4,10

    Studies of the maternal RSVpreF vaccine show that the most common side effects for pregnant individuals are redness or soreness at the injection site, muscle aches, and headaches.10,12 These symptoms are usually mild and go away on their own after a short time.10

    Similarly, the most common side effects of Nirsevimab are pain, redness, or swelling at the injection site.13,14 No serious allergic reactions were reported during the clinical trials.14

  • If you are sick and have a fever, it's better to wait until you feel better to get the maternal RSV vaccine. You should not get the maternal vaccine if you have had a severe allergic reaction, like anaphylaxis, to any component in the vaccine.

  • If your symptoms last longer than a couple of days, or if you are worried about how you feel after your vaccination, you can call your doctor or get help by calling the toll-free health information and advice phone service available in your province/territory:

    • British Columbia, Alberta, Saskatchewan, Ontario, Quebec, New Brunswick, Nova Scotia, Newfoundland and Labrador, New Brunswick, Prince Edward Island, the Yukon, the Northwest Territories: Call 811

    • Manitoba: Call 1-888-315-9257

    • Nunavut: Call 211

    You can also get help by visiting your nearest emergency department or urgent care centre. If you develop any serious symptoms that you think could be an allergic reaction after your vaccination, call emergency services right away by dialling 911.

RSV Vaccine Timing

  • The maternal vaccine is recommended between 32 and 36 weeks of pregnancy. It’s best to get the maternal RSVpreF vaccine soon before or during the RSV season. In Canada, the RSV season typically begins in late fall and lasts until spring, with most cases occurring between December through March. Talk with your healthcare provider for more information on when you can get the maternal RSV vaccine.

  • Yes! There is data available showing that you can safely get the maternal RSVpreF vaccine at the same time as the flu and Tdap vaccines.4,15 There is no data available yet on getting the maternal RSVpreF vaccine and COVID-19 vaccines together.4 Talk to your healthcare provider for more information on the best time to get vaccinated.

  • As of June 2024, only one dose (shot) of the maternal RSVpreF vaccine is recommended for pregnant people. Currently, there is not enough data to determine whether another dose might be needed in later pregnancies.4,14 The National Advisory Committee on Immunization (NACI) will continue to monitor the latest data and will update this recommendation once more information is available.

  • Yes, you can still get the maternal RSVpreF vaccine even if you've had an RSV infection before.4 Getting the vaccine boosts your immunity (protection) against RSV and helps make sure you and your baby are protected against future RSV infections.

Additional Information

  • The maternal RSVpreF vaccine is available at pharmacies. Pregnant individuals can check the maternal RSV website to find participating pharmacies (https://www.abrysvo.com/find-a-vaccine).

    As of June 2024, it's uncertain whether all Canadian provinces and territories will have the infant RSV antibody (Nirsevimab) available for the 2024 RSV season, or if it will be offered to all babies or only those at highest risk. Talk to your healthcare provider about RSV protection for your baby. They can advise you on the best options based on your baby's age, health, and the current availability of Nirsevimab.

  • Getting the maternal RSV vaccine during pregnancy or the infant RSV antibody for your baby are the best ways to protect against RSV infection. It’s also a good idea to keep small babies away from people who are sick and to encourage anyone in your household who is sick to cover their mouth when they cough or sneeze and to wash their hands regularly. If possible, breastfeed your baby, as breast milk contains antibodies that can help protect against RSV infection.

Both the maternal RSVpreF vaccine and the infant antibody help protect babies from severe illness and hospitalization.

Key Facts

  • RSV is a common virus that spreads easily through coughing, sneezing, and touching contaminated surfaces. It usually causes cold-like symptoms, but for babies and older adults, it can lead to serious lung infections and breathing problems. RSV is most active in the fall and winter months.

  • Babies under 6 months are more likely to get very sick from RSV and may need hospital care. RSV can cause serious breathing problems and lead to lung infections like bronchiolitis and pneumonia. RSV is a leading cause of hospitalization in babies under 1 year old.

  • Pregnant people can get the RSV vaccine (RSVpreF) between 32 and 36 weeks of pregnancy, or newborns can receive an RSV antibody injection (Nirsevimab) shortly after birth. The best option depends on what’s available in your area, cost, and your personal preference.

  • When you get the RSVpreF vaccine between 32 and 36 weeks of pregnancy, your body passes infection-fighting antibodies to your baby through the placenta. This protection helps prevent severe RSV illness in your baby’s first few months of life when they need it the most.

  • Unlike vaccines, which help the body build its own protection (antibodies), the infant RSV antibody injection gives babies ready-made antibodies that start working right away to protect them from RSV for at least 5 months, which is the length of a typical RSV season.

  • As of 2025, Ontario is the only province that covers the cost of the maternal RSV vaccine. In most other provinces and territories, it is not covered by public health programs but can be purchased with a prescription at select pharmacies. Some private insurance plans may help cover the cost.

  • As of 2025, the infant RSV antibody (Nirsevimab) is only available through public health programs and cannot be purchased at pharmacies. Some provinces, like Ontario, offer it for free to eligible babies. Other provinces may offer it only to babies at higher risk, such as those born prematurely or with certain health conditions.

  • Your healthcare provider can help you understand whether the maternal RSV vaccine or the infant RSV antibody is the right choice for you and your baby. They can also give you the most up-to-date information on availability, eligibility, and cost in your area.

    1. Public Health Agency of Canada. Respiratory syncytial virus (RSV) vaccines: Canadian Immunization Guide [Internet]. Ottawa (ON): Public Health Agency of Canada; 2024 Aug 9 [cited 2024 Nov 5]. Available from: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines/respiratory-syncytial-virus.html

    2. Bourdeau M, Mitchell I, Grubb E, Defoy I. Pediatric RSV-associated hospitalizations before and during the COVID-19 pandemic. JAMA Netw Open. 2023;6(10). doi:10.1001/jamanetworkopen.2023.36863

    3. Mitchell I, Defoy I, Grubb E. Burden of respiratory syncytial virus hospitalizations in Canada. Can Respir J. 2017;2017:4521302.  DOI: 10.1155/2017/4521302

    4. National Advisory Committee on Immunization [NACI]. Statement on the prevention of respiratory syncytial virus (RSV) disease in infants [Internet]. Ottawa (ON): Public Health Agency of Canada; 2024 May 17 [cited 2024 Jun 5]. Available from: https://www.canada.ca/content/dam/phac-aspc/documents/services/publications/vaccines-immunization/national-advisory-committee-immunization-statement-prevention-respiratory-syncytial-virus-disease-infants/naci-statement-2024-05-17.pdf

    5. Baraldi, E., et al. (2022). RSV disease in infants and young children: Can we see a brighter future? Hum Vaccin Immunother, 18(4), 2079322.

    6. Rha B, Dahl RM, Moyes J, et al. Respiratory syncytial virus-associated hospitalizations among young children: 2015-2016. Pediatrics. 2020;146(1)

    7. Cohen C, Zar HJ. Deaths from RSV in young infants-the hidden community burden. Lancet Glob Health. 2022;10(2)

    8. Hause AM, Avadhanula V, Aideyan L, et al. Adverse outcomes in pregnant women hospitalized with respiratory syncytial virus infection: A case series. Clin Infect Dis. 2021;72(1):138-140.

    9. Griffin MP, Yuan Y, Takas T, et al. Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med. 2020;383(5):415-425.

    10. Kampmann B, Jones CE, Munoz FM, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464.

    11. Simões EAF, Center KJ, Tita AT, et al. Prefusion F protein-based respiratory syncytial virus immunization in pregnancy. N Engl J Med. 2022;386(17):1615-1626.

    12. Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115–1122.

    13. Pfizer. Respiratory syncytial virus stabilized bivalent prefusion F subunit vaccine (RSVPREF / ABRYSVO) [Briefing document from Vaccines and Related Biological Products Advisory Committee Meeting] [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2023 May 18 [cited 2024 Nov 5]. Available from: https://www.fda.gov/media/168186/download

    14. Centers for Disease Control and Prevention. Immunizations to protect infants [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2023 Aug 9 [cited 2024 Nov 5]. Available from: https://www.cdc.gov/rsv/immunizations-protect-infants/index.html

    15. Centers for Disease Control and Prevention. Frequently asked questions about RSVpreF (Abrysvo) vaccine for pregnant people [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; 2023 Nov 13 [cited 2024 Nov 5]. Available from: https://www.cdc.gov/vaccines/vpd/rsv/hcp/pregnant-people-faqs.html